Susquehanna Fundamental Investments LLC Increases Position in Novavax, Inc. (NASDAQ:NVAX)

Susquehanna Fundamental Investments LLC lifted its stake in Novavax, Inc. (NASDAQ:NVAX) by 9.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 343,414 shares of the biopharmaceutical company’s stock after purchasing an additional 29,834 shares during the quarter. Susquehanna Fundamental Investments LLC’s holdings in Novavax were worth $4,348,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Shah Capital Management lifted its stake in shares of Novavax by 19.0% in the second quarter. Shah Capital Management now owns 9,662,090 shares of the biopharmaceutical company’s stock worth $122,322,000 after buying an additional 1,544,263 shares in the last quarter. Edgestream Partners L.P. boosted its stake in Novavax by 23.7% during the 1st quarter. Edgestream Partners L.P. now owns 12,753 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 2,447 shares during the last quarter. ProShare Advisors LLC increased its holdings in shares of Novavax by 29.9% in the 1st quarter. ProShare Advisors LLC now owns 37,203 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 8,570 shares in the last quarter. Swiss National Bank lifted its holdings in shares of Novavax by 17.1% during the first quarter. Swiss National Bank now owns 211,000 shares of the biopharmaceutical company’s stock valued at $1,009,000 after purchasing an additional 30,800 shares in the last quarter. Finally, Allianz Asset Management GmbH lifted its holdings in shares of Novavax by 45.9% during the fourth quarter. Allianz Asset Management GmbH now owns 634,692 shares of the biopharmaceutical company’s stock valued at $3,047,000 after purchasing an additional 199,771 shares in the last quarter. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax Stock Up 9.5 %

Shares of NASDAQ:NVAX opened at $13.30 on Monday. The stock has a market capitalization of $1.87 billion, a PE ratio of -4.20 and a beta of 2.04. The firm’s 50 day moving average price is $12.76 and its 200-day moving average price is $10.95. Novavax, Inc. has a twelve month low of $3.53 and a twelve month high of $23.86.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.82 by ($0.83). The business had revenue of $415.50 million for the quarter, compared to analyst estimates of $458.57 million. During the same quarter in the previous year, the firm earned $0.58 EPS. The company’s revenue for the quarter was down 2.1% on a year-over-year basis. Analysts expect that Novavax, Inc. will post -1.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on NVAX shares. B. Riley reissued a “buy” rating and issued a $23.00 target price (down previously from $25.00) on shares of Novavax in a research report on Monday, August 12th. JPMorgan Chase & Co. boosted their price objective on shares of Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a report on Monday, August 12th. Finally, Bank of America raised their target price on shares of Novavax from $12.00 to $18.00 and gave the stock a “neutral” rating in a report on Friday, June 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Novavax presently has a consensus rating of “Hold” and an average target price of $15.80.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.